Efficacy and features of balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: a narrative review
Author:
Open Access
- 1 July 2024
- journal article
- review article
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 9, 48
Abstract
Background and Objective: Systemic therapy for hepatocellular carcinoma (HCC) is recommended in transarterial chemoembolization (TACE)-refractory and unsuitable cases. In Japan, TACE is broadly classified into conventional TACE (C-TACE), balloon occluded TACE (B-TACE), and drug-eluting beads TACE. However, the type of TACE recommended for TACE-refractory or unsuitable cases has not been elucidated, and a targeted approach for individual cases and appropriate TACE selection is important. B-TACE is considered a valuable therapeutic option in the management of HCC. The technique involves the precise placement of a microcatheter with a balloon into the target hepatic artery, followed by selective occlusion of the hepatic artery, including tumor-feeding vessels, using the balloon. By leveraging the hemodynamic changes resulting from arterial occlusion, B-TACE enables effective accumulation of chemotherapeutic agents within the tumor. Incorporating B-TACE into the treatment strategy for HCC is of utmost importance. Therefore, this article provides an overview of the technique. Methods: A comprehensive review of all available literature in the English language through December 1, 2023 utilizing PubMed was conducted. Key Content and Findings: In the intermediate stage, TACE and systemic therapy play complementary roles, and it is important to select a treatment strategy that considers tumor status and hepatic reserve. However, no study has investigated the various types of TACE in the treatment of such patients. Currently, TACE in Japan is broadly classified into C-TACE, B-TACE, and drug-eluting beads TACE (DEB-TACE). This article outlines the evolution of B-TACE for HCC. We identified retrospective and prospective studies evaluating B-TACE. In this review, we evaluate data on B-TACE for HCC. Conclusions: In the era of systemic therapy, B-TACE may play a complementary and synergy effect role.Keywords
This publication has 41 references indexed in Scilit:
- Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: Incidence, diagnosis, treatment, outcome and mechanismCritical Reviews in Oncology/Hematology, 2011
- A Randomized Phase II Study of Drug-Eluting Beads versus Transarterial Chemoembolization for Unresectable Hepatocellular CarcinomaOnkologie, 2011
- Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma.2009
- Implication of Frequent Local Ablation Therapy for Intrahepatic Recurrence in Prolonged Survival of Patients With Hepatocellular Carcinoma Undergoing Hepatic ResectionAnnals of Surgery, 2006
- Usefulness of prophylactic transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection.2005
- The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinomaLiver Transplantation, 2004
- Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomyJournal of Hepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Hepatic artery embolization in 120 patients with unresectable hepatoma.Radiology, 1983